Skip to main content

Table 4 Multivariate analysis of factors associated with good clinical outcomes among patients treated for MDR-TB

From: Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss

  Good treatment outcomes among all MDR TB patients aOR (95% CI) Good treatment outcomes (excluding patients with hearing loss diagnosed clinically) aOR (95% CI) Good treatment outcomes (excluding patients with hearing loss diagnosed by audiometry) aOR (95% CI)
Sex Female 1.00 1.00 1.00
  Male 0.72 (0.4 –1.21) 0.71 (0.42 – 1.19) 0.72 (0.44 – 1.21)
HIV status HIV infection 0.64 (0.37 –1.12) 0.70 (0.39 – 1.20) 0.66 (0.38 – 1.15)
TB treatment history Never treated for TB before 1.00 1.00 1.00
New TB regimen 0.93 (0.27 – 3.23) 0.71 (0.19 – 2.64) 0.75 (0.20 – 2.77)
Retreatment regimen 0.60 (0.18 – 1.98) 0.48 (0.13 – 1.69) 0.48 (0.14 – 1.70)
*Treated for MDR TB 0.16(0.09 – 0.67) 0.12 (0.02 – 0.70) 0.11 (0.02 – 0.57)
Renal failure at any point 0.61 (0.36 – 0.98) 0.46 (0.22 – 0.94) 0.52 (0.12 – 1.01)
Duration of amikacin treatment (in months) 1.13(1.06 – 1.21) 1.14 (1.06 – 1.21) 1.14 (1.05 – 1.22)
Mean dose of amikacin per kilogram per month 1.90 (1.12 – 2.99) 1.90 (1.79 – 3.00) 1.88 (1.18 – 3.99)
  1. *History of MDR–TB treatment before enrolment in the study, Minimum dose 13 mg/kg.